• FirefoxInstall the new Firefox »
  •  Dow Up0.19% Nasdaq Up0.57%

    Oncothyreon Inc (ONTY)

    1.65 Up 0.04(2.48%) Mar 27, 4:00PM EDT
    |After Hours : 1.62 Down 0.04 (2.12%) Mar 27, 5:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Oncothyreon Inc
    2601 Fourth Avenue
    Suite 500
    Seattle, WA 98121
    United States - Map
    Phone: 206-801-2100
    Fax: 206-801-2101
    Website: http://www.oncothyreon.com

    Index Membership:N/A
    Full Time Employees:49

    Business Summary 

    Oncothyreon Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of cancer. Its product candidate includes Tecemotide, a vaccine for the treatment of non-small cell lung cancer. The company is also developing ONT-10, a cancer vaccine, which is in Phase I clinical trial for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate cancers, as well as various lung cancer; ONT-380, a small-molecule HER2 inhibitor that is in Phase Ib trial for the treatment of metastatic breast cancer, including patients with brain metastases; and PX-866, which has completed two Phase II trials for the treatment of various cancers. In addition, it develops PET lipid-A, a proprietary synthetic lipid-A analog. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Oncothyreon Inc

    Corporate Governance 
    Oncothyreon Inc’s ISS Governance QuickScore as of Mar 1, 2015 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Robert L. Kirkman M.D., 66
    Chief Exec. Officer, Pres and Director
    Ms. Julia M. Eastland M.B.A., 51
    Chief Financial Officer, Principal Accounting Officer, VP of Corp. Devel. and Sec.
    Mr. Gary Christianson PE, 60
    Chief Operating Officer
    Dr. Scott Robert Peterson Ph.D., 53
    Chief Scientific Officer
    Dr. Diana F. Hausman M.D., 52
    Chief Medical Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders